Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis | Zendy

N. Hertel | Zendy; Kotchie | Zendy; Yevgeniy Samyshkin | Zendy; Radford | Zendy; Humphreys | Zendy; Jameson | Zendy

Open Access

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis

Author(s) -

N. Hertel,

Kotchie,

Yevgeniy Samyshkin,

Radford,

Humphreys,

Jameson

Publication year - 2012

Publication title -

international journal of copd

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 67

eISSN - 1178-2005

pISSN - 1176-9106

DOI - 10.2147/copd.s29820

Subject(s) - medicine , lama , roflumilast , copd , exacerbation , cost effectiveness , cost effectiveness analysis , incremental cost effectiveness ratio , salmeterol , quality adjusted life year , intensive care medicine , risk analysis (engineering)

Frequent exacerbations which are both costly and potentially life-threatening are a major concern to patients with chronic obstructive pulmonary disease (COPD), despite the availability of several treatment options. This study aimed to assess the lifetime costs and outcomes associated with alternative treatment regimens for patients with severe COPD in the UK setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research